There are various treatment options for patients with multiple myeloma (MM), including autologous hematopoietic stem cell transplantation (HSCT),...
Myeloma NZ
Georgia woman hopes experimental “living” cancer therapy will stop her myeloma
For 48-year old Atlanta mom, wife and dog groomer Cheri Letts, the realization she was sick came slowly. "I was starting to feel rundown, and it...
Advances Could Lead to Curative Strategies in Myeloma
There are currently 10 FDA-approved treatments in the multiple myeloma space; however, a more personalized therapy could be key to finding a cure,...
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
Background:Â The refractory/relapsed multiple myeloma (RRMM) remains a big clinical challenge, due to its biological and clinical complexity. Leading...
Two molecules offer great potential to combat cancer and chronic infections
To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy...
New guidelines help ensure optimal outcomes for children treated with CAR-T Cell Therapy
While chimeric antigen receptor (CAR)-T cell therapy has demonstrated positive response rates in children with relapsed and/or refractory...
Could athersys play a role in the progression of CAR-T Therapy?
One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands...
Advances in T cell therapy may fight cancer without side effects
The human immune system is truly a wonder. It plays a critical role in our body’s defense to invading disease. Like a home security system, it is on...
AI enables personalized treatment for myeloma
A multidisciplinary team of researchers has developed an artificial intelligence platform that could enable doctors to prescribe personalized...
Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with...
Minimal residual disease analysis in myeloma – when, why and where
The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the...
Many questions to ask in setting national coverage for CAR-T Therapies
Next week, a CMS committee will hold a daylong meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell...